Physician profile
Robin C Davis
NPI 1265722037
$7,590.46
in general payments reported to CMS, 2019-2025
13 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $125 · 2021: $292 · 2022: $144 · 2023: $5,570 · 2024: $711 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,938 · Food and Beverage: $1,903 · Travel and Lodging: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,937.50 |
| Food and Beverage | $1,902.56 |
| Travel and Lodging | $1,028.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $5,988.47 | 2020-2025 | Xcopri |
| Ucb, INC. | $627.91 | 2019-2025 | Briviact, Fintepla |
| Jazz Pharmaceuticals INC. | $551.47 | 2022-2025 | |
| Nevro Corp. | $98.62 | 2019 | |
| Advanced Oxygen Therapy INC. | $63.05 | 2025 | Topical Oxygen Chamber For Extremities |
| Amgen INC. | $49.88 | 2019-2021 | |
| Eisai INC. | $49.32 | 2021 | |
| Sunovion Pharmaceuticals INC. | $45.67 | 2020 | |
| Novartis Pharmaceuticals Corporation | $39.49 | 2019-2020 | |
| Abbvie INC. | $38.40 | 2024 | |
| Sumitomo Pharma America, INC. | $15.71 | 2023 | Aptiom |
| Neurocrine Biosciences, INC. | $11.80 | 2020 | |
| Aucta Pharmaceuticals, INC. | $10.67 | 2024 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.